Non-small cell lung cancer (NSCLC) tumors with specific mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been defined as 'oncogene addicted'to indicate …

Objectives In the first-line treatment of non-small cell lung cancer (NSCLC) harboring EGFR
mutations, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has …

EGFR mutations are well established as important oncogenic drivers that occur in 10–44%
of primary lung adenocarcinomas occurring more frequently in women, Asians and non …

Introduction Although standard schedule of gefitinib was the administration of 250 mg tablet
every day, many patients need dose reduction because of toxicities. However, the efficacy of …

Erlotinib is one of the treatment choices for patients with advanced non‑small cell lung
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …

Purpose: Erlotinib and gefitinib are both tyrosine kinase inhibitors (TKIs) approved for the
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …

An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor
receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR …

Background Patients with epidermal growth factor receptor (EGFR) activation mutation-
positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase …

8011 Background: HM61713 is a novel, oral, selective inhibitor for EGFR mutations
including both activating mutations and T790M, but not EGFR wild-type. This phase 1 trial …

Aim: The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged
PFS and OS of patients with NSCLC. However, outcome of the combination therapy are …